Ultragenyx Pharmaceutical Inc (RARE) VP Theodore Alan Huizenga Sells 1,338 Shares

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) VP Theodore Alan Huizenga sold 1,338 shares of Ultragenyx Pharmaceutical stock in a transaction on Wednesday, June 13th. The shares were sold at an average price of $76.97, for a total transaction of $102,985.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of RARE stock traded up $3.47 on Thursday, reaching $81.56. 589,344 shares of the company were exchanged, compared to its average volume of 546,673. The stock has a market capitalization of $3.97 billion, a P/E ratio of -10.53 and a beta of 1.97. Ultragenyx Pharmaceutical Inc has a 1 year low of $41.67 and a 1 year high of $82.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Monday, May 7th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.81. The business had revenue of $10.68 million for the quarter, compared to analyst estimates of $56.58 million. During the same quarter in the previous year, the firm posted ($1.63) earnings per share. equities research analysts expect that Ultragenyx Pharmaceutical Inc will post -5.32 earnings per share for the current year.

RARE has been the subject of a number of recent analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and issued a $74.00 price objective (down previously from $85.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 21st. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $66.00 price objective (down previously from $68.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 21st. Morgan Stanley reaffirmed an “equal weight” rating and issued a $60.00 price objective (up previously from $57.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 21st. Bank of America boosted their target price on shares of Ultragenyx Pharmaceutical from $60.00 to $61.00 and gave the stock a “buy” rating in a research note on Wednesday, February 21st. Finally, Robert W. Baird reissued a “buy” rating and set a $70.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of “Buy” and a consensus price target of $70.06.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Profund Advisors LLC boosted its position in Ultragenyx Pharmaceutical by 5.6% during the first quarter. Profund Advisors LLC now owns 16,653 shares of the biopharmaceutical company’s stock worth $849,000 after acquiring an additional 889 shares during the last quarter. American Century Companies Inc. boosted its position in Ultragenyx Pharmaceutical by 2.8% during the first quarter. American Century Companies Inc. now owns 36,720 shares of the biopharmaceutical company’s stock worth $1,872,000 after acquiring an additional 997 shares during the last quarter. Wells Fargo & Company MN boosted its position in Ultragenyx Pharmaceutical by 5.0% during the first quarter. Wells Fargo & Company MN now owns 24,200 shares of the biopharmaceutical company’s stock worth $1,234,000 after acquiring an additional 1,149 shares during the last quarter. RMB Capital Management LLC boosted its position in Ultragenyx Pharmaceutical by 3.3% during the first quarter. RMB Capital Management LLC now owns 45,178 shares of the biopharmaceutical company’s stock worth $2,304,000 after acquiring an additional 1,445 shares during the last quarter. Finally, Verity Asset Management Inc. boosted its position in Ultragenyx Pharmaceutical by 26.4% during the first quarter. Verity Asset Management Inc. now owns 7,245 shares of the biopharmaceutical company’s stock worth $369,000 after acquiring an additional 1,512 shares during the last quarter. Hedge funds and other institutional investors own 96.11% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply